Clinical Study “Relaxin for Heart Failure with preserved Ejection Fraction (HFpEF)”

2024-11-19T13:36:48+01:0011.2020|

Relaxera is designing a clinical phase II study demonstrating the beneficial and pleiotropic effects of relaxin in heart failure with preserved ejection fraction (HFpEF). Relaxera plan to commence this study during 2025, Q4. The selection of patients for this upcoming study is the responsibility of the Prinicipal Investigators (the physicians in charge of conducting the [...]

Relaxera and University of Pittsburgh announce research cooperation

2022-12-16T17:54:26+01:0003.2018|

As of December 2017, Relaxera and the group of Prof. Guy Salama (Heart and Vascular Institute of The University of Pittsburgh) entered into a research cooperation regarding the effects of relaxin in an animal model of HFpEF (“aged rat”). The focus of this research will, among others, be on relaxin’s effects towards isoform expression and [...]

© Copyright , Relaxera Pharmazeutische Gesellschaft mbH & Co. KG
Go to Top